Beta secretase inhibitor KMI-574 Alzheimer's Disease Research Wako

KMI-574 produced by FUJIFILM Wako Chemical Corporation

Amyloid precursor protein (APP) is an integral membrane protein expressed in many tissues with concentrated expression in neuron synapses. Whilst it's primary function is uncertain it is best known as the precursor of Aβ which accumulates in the brains of Alzheimer's sufferers. APP is subject to cleavage by the proteolytic secretase enzymes (ɑ-, β - and γ-secretase). The predominant processing pathway for APP is proteolysis by ɑ-secretase, because this cleaves APP within the fragment that gives rise to Aβ the ɑ-secretase pathway precludes Aβ formation. Cleavage of APP by β–secretase (also known as β–site APP Cleaving enzyme 1 or BACE1) results leaves a membrane bound fragment known as C99 which following the action of γ–secretase produces Aβ. This has led to interest in β -secretase inhibitors which might prevent or slow the build-up of Aβ and be of therapeutic use in the management of Alzheimer's disease.

KMI-574 is a β-secretase inhibitor produced from KMI-429 by substituting the side chain with bioequivalent material to enhance blood-brain barrier permeability.

KMI-574 1mg

IC₅₀ = 5.6 nmol/L

Molecular Formula=C₃₉H₄₉FN₁₂O₈

Molecular Weight:832.88

CAS: 753030-74-9

Store at -20°C

For cell biology
Research Use Only (RUO) - not for administration to humans